Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.51 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.51 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.51 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.51 |
| ▸ | APP | P05067 | 3/20 | 0.50 |
| ▸ | BCHE | P06276 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.49 |
| ▸ | MERTK | Q12866 | 5/20 | 0.49 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.47 |
| ▸ | TCF7L2 | Q9NQB0 | 3/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14266657 | 0.94 | EHMT2 (0.48) | CXCR4EHMT2DNMT3ATLR7APP | |
| SCHEMBL14256774 | 0.88 | APP (0.60) | CXCR4EHMT2DNMT3AAPPBCHE | |
| SCHEMBL14256532 | 0.86 | EHMT2 (0.66) | CXCR4EHMT2DNMT3AAPPBCHE | |
| SCHEMBL14266672 | 0.84 | MERTK (0.57) | CXCR4EHMT2DNMT3AAPPBCHE | |
| SCHEMBL14256525 | 0.84 | CXCR4 (0.56) | CXCR4EHMT2DNMT3AAPPBCHE | |
| SCHEMBL14256548 | 0.81 | APP (0.57) | CXCR4EHMT2DNMT3AAPPBCHE | |
| SCHEMBL14256529 | 0.81 | MERTK (0.72) | CXCR4EHMT2DNMT3AAPPBCHE | |
| SCHEMBL14256544 | 0.80 | CXCR4 (0.54) | CXCR4EHMT2DNMT3AAPPBCHE | |
| SCHEMBL14256527 | 0.79 | APP (0.64) | CXCR4EHMT2DNMT3ATLR7APP | |
| SCHEMBL14266660 | 0.79 | MERTK (0.52) | CXCR4EHMT2DNMT3AAPPBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058312-A1 | Modulators of hepatocyte growth factor/c-Met activity | ANGION BIOMEDICA CORPORATION (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058312-A1 | Modulators of hepatocyte growth factor/c-Met activity | ANGION BIOMEDICA CORPORATION (US) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058312-A1 | Modulators of hepatocyte growth factor/c-Met activity | HGF, MET, HDGF | CXCR4 958/4885EHMT2 1177/4885DNMT3A 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.